MedTrace Logo

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

NCT06019507 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.

Conditions

  • Liver Transplantation

Interventions

BIOLOGICAL

TCD601

Investigational Product

BIOLOGICAL

Cyclophosphamide

Conditioning Regimen

DRUG

TAC

Immunosuppression Therapy

DRUG

MMF

Immunosuppression Therapy

DRUG

Corticosteroids

Immunosuppression Therapy

Sponsors & Collaborators

  • ITB-Med LLC

    lead INDUSTRY

Principal Investigators

  • Kellie Kennon, BSN · ITB-MED

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2026-06-30
Completion
2029-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06019507 on ClinicalTrials.gov